Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4227 Evaluation of circulating extracellular vesicles as suitable prognostic markers in MEN1-associated non-functioning pancreatic neuroendocrine neoplasia

Introduction: Non-functioning pancreatic neuroendocrine neoplasias (NF-pNENs) significantly contribute to premature death of multiple endocrine neoplasia type 1 (MEN1) patients. Reliable prognostic markers for disease progression are lacking. Circulating liquid biomarkers, including microRNAs and Long-non-Coding (LnC) RNAs in extracellular vesicles, are emerging as new prognostic tools.

Conference:

Presenting Author:

Authors: Manoharan J, Khizanishvili N, Krasser-Gercke N, Albers M, Mintziras I,

Keywords: Multiple endokrine neoplasia type 1, Extracellular vesicles, Non-functioning pancreatic neuroendocrine neoplasia, exosomal-LnC-RNA NEAT1, exosomal miRNA451a,

#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).

Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barriuso J, Lamarca A, McNamara M, Manoharan P, Moghadam S,

Keywords: pNETs, WES, everolimus, sunitinib,

#1759 Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Manoharan P

Authors: Manoharan P, Navalkissoor S, Lamarca A, Calero J, Chan P,

Keywords: SomaKit, DOTATOC, GEP-NET,

#1486 Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1

Introduction: The role of minimally invasive pancreatic surgery for pancreatic neuroendocrine neoplasms (pNENs) in patients with multiple endocrine neoplasia type 1 (MEN1) is not well defined.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lopez C

Authors: Lopez C, Albers M, Bollmann C, Manoharan J, Waldmann J,

Keywords: pancreatic neuroendocrine neoplasm, laparoscopic pancreatic resection, MEN1,

#1438 An Unusual Phenotype of Multiple Endocrine Neoplasia Type 1 with a Small Intestine Neuroendocrine Tumor Associated with Large Deletion of the MEN1 Gene

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome that is caused by germline mutations in the Menin suppressor gene on chromosome 11q13. Small intestine neuroendocrine neoplasias (SI-NEN) are currently not considered to be part of the phenotype of the MEN1-syndrome.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Manoharan J, L. Lopez C, Hackmann K, Albers M, Pehl A,

Keywords: MEN1, Deletion mutation, SI-NEN,